Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 16/20 | 0.43 |
| ▸ | CHRM2 known ✓ | P08172 | 8/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13240947 | 0.99 | CHRM3 (0.41) | CHRM3CHRM2NPSR1CHRM1KMT2A | |
| SCHEMBL3778319 | 0.97 | CHRM3 (0.41) | CHRM3CHRM2NPSR1CHRM1KMT2A | |
| Bromide SCHEMBL2485675 | 0.96 | CHRM3 (0.43) | CHRM3CHRM2NPSR1CHRM1KMT2A | |
| SCHEMBL16664430 | 0.95 | CHRM3 (0.41) | CHRM3CHRM2NPSR1CHRM1CYP2D6 | |
| SCHEMBL13240869 | 0.95 | CHRM3 (0.41) | CHRM3CHRM2NPSR1CHRM1KMT2A | |
| SCHEMBL3780781 | 0.95 | CHRM3 (0.41) | CHRM3CHRM2NPSR1CHRM1KMT2A | |
| SCHEMBL13240907 | 0.95 | CHRM3 (0.41) | CHRM3CHRM2NPSR1CHRM1KMT2A | |
| SCHEMBL13240977 | 0.95 | CHRM3 (0.41) | CHRM3CHRM2NPSR1CHRM1CYP2D6 | |
| SCHEMBL15127407 | 0.94 | CHRM3 (0.39) | CHRM3CHRM2NPSR1CHRM1KMT2A | |
| SCHEMBL12072382 | 0.94 | CHRM3 (0.39) | CHRM3CHRM2NPSR1CHRM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376489-B1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2015-04-22 | — | — | EP | claimed |
| US-8455646-B2 | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-04 | — | — | US | claimed |
| EP-2376489-A1 | Alkaloid aminoester derivatives and medicinal composition thereof | Chiesi Farmaceutici S.p.A. (IT) | 2011-10-19 | — | — | EP | claimed |
| US-20100173880-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-08 | — | — | US | claimed |
| WO-2010072338-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-01 | — | — | WO | claimed |
| EP-2376489-B1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2015-04-22 | — | — | EP | disclosed |
| US-8835682-B2 | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20130196978-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| US-8455646-B2 | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-04 | — | — | US | disclosed |
| US-20100173880-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196978-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM1, CHRNG | CHRM3 1/4885CHRM2 4/4885CHRM1 2/4885 |
| US-20100173880-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM1, CHRNG | CHRM3 1/4885CHRM2 4/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.